EMERYVILLE, CA, Totus Medicines, a company revolutionizing small molecule drug discovery and development, announced it has closed a $66M Series B financing led by DCVC Bio.
Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio.
The company closed the final tranche of a Series B financing totaling $66 million, led by DCVC Bio and including the participation of North Pond Ventures, Camford Capital, and the Regents of the University of Minnesota.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
